Literature DB >> 23510830

Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages.

Nanlan Luo1, B Hong Chung, Xiangdong Wang, Richard L Klein, Chao-Ke Tang, W Timothy Garvey, Yuchang Fu.   

Abstract

OBJECTIVE: Adiponectin is one of several important, metabolically active cytokines secreted from adipose tissue. Epidemiologic studies have associated low circulating levels of this adipokine with multiple metabolic disorders including obesity, insulin resistance, type II diabetes, and cardiovascular disease. To investigate how enhanced adiponectin-mediated changes in metabolism in vivo, we generated transgenic mice which specifically overexpress the gene coding for adiponectin receptor 1 (AdipoR1) in mouse macrophages using the human scavenger receptor A-I gene (SR-AI) enhancer/promoter. We found that macrophage-specific AdipoR1 transgenic mice (AdR1-TG) presented reduced whole body weight, fat accumulation and liver steatosis when these transgenic mice were fed with a high fat diet. Moreover, these macrophage AdR1-TG mice exhibited enhanced whole-body glucose tolerance and insulin sensitivity with reduced proinflammatory cytokines, MCP-1 and TNF-α, both in the serum and in the insulin target metabolic tissues. Additional studies demonstrated that these macrophage AdR1-TG animals exhibited reduced macrophage foam cell formation in the arterial wall when these transgenic mice were crossed with a low-density lipoprotein receptor (Ldlr) deficient mouse model.
CONCLUSIONS: These results suggest that AdipoR1 overexpressed in macrophages can physiologically modulate metabolic activities in vivo by enhancing adiponectin actions in distal metabolically active tissues. The AdipoR1 modified macrophages provide unique interactions with the residented tissues/cells, suggesting a novel role of macrophage adiponectin receptor in improving metabolic disorders in vivo.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23510830      PMCID: PMC3640696          DOI: 10.1016/j.atherosclerosis.2013.02.026

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  51 in total

1.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.

Authors:  A H Berg; T P Combs; X Du; M Brownlee; P E Scherer
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

2.  Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.

Authors:  Taiki Ohashi; Rei Shibata; Takeshi Morimoto; Masaaki Kanashiro; Hideki Ishii; Satoshi Ichimiya; Takafumi Hiro; Katsumi Miyauchi; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Takeshi Kimura; Hiroyuki Daida; Toyoaki Murohara; Masunori Matsuzaki
Journal:  Atherosclerosis       Date:  2010-05-11       Impact factor: 5.162

3.  GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects.

Authors:  Da Young Oh; Saswata Talukdar; Eun Ju Bae; Takeshi Imamura; Hidetaka Morinaga; WuQiang Fan; Pingping Li; Wendell J Lu; Steven M Watkins; Jerrold M Olefsky
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

4.  Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages.

Authors:  N Ouchi; S Kihara; Y Arita; M Nishida; A Matsuyama; Y Okamoto; M Ishigami; H Kuriyama; K Kishida; H Nishizawa; K Hotta; M Muraguchi; Y Ohmoto; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  2001-02-27       Impact factor: 29.690

Review 5.  Atherosclerosis.

Authors:  A J Lusis
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

6.  Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses.

Authors:  Ling Tian; Nanlan Luo; Xiaolin Zhu; Byung-Hong Chung; W Timothy Garvey; Yuchang Fu
Journal:  Atherosclerosis       Date:  2011-12-22       Impact factor: 5.162

7.  Association between plasma high-molecular-weight adiponectin and coronary plaque characteristics assessed by computed tomography angiography in conditions of visceral adipose accumulation.

Authors:  Eiji Kunita; Hideya Yamamoto; Toshiro Kitagawa; Norihiko Ohashi; Hiroto Utsunomiya; Toshiharu Oka; Jun Horiguchi; Kazuo Awai; Yasuki Kihara
Journal:  Circ J       Date:  2012-04-10       Impact factor: 2.993

Review 8.  Adiponectin receptor as a key player in healthy longevity and obesity-related diseases.

Authors:  Toshimasa Yamauchi; Takashi Kadowaki
Journal:  Cell Metab       Date:  2013-01-24       Impact factor: 27.287

9.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.

Authors:  J Fruebis; T S Tsao; S Javorschi; D Ebbets-Reed; M R Erickson; F T Yen; B E Bihain; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

10.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Authors:  T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

View more
  21 in total

1.  Macrophage polarization phenotype regulates adiponectin receptor expression and adiponectin anti-inflammatory response.

Authors:  Caroline M W van Stijn; Jason Kim; Aldons J Lusis; Grant D Barish; Rajendra K Tangirala
Journal:  FASEB J       Date:  2014-11-12       Impact factor: 5.191

Review 2.  Cardiometabolic effects of adiponectin.

Authors:  Jennifer L Parker-Duffen; Kenneth Walsh
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-09-13       Impact factor: 4.690

3.  Insulin-independent role of adiponectin receptor signaling in Drosophila germline stem cell maintenance.

Authors:  Kaitlin M Laws; Leesa L Sampson; Daniela Drummond-Barbosa
Journal:  Dev Biol       Date:  2015-01-07       Impact factor: 3.582

Review 4.  The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.

Authors:  Marina Nati; Kyoung-Jin Chung; Triantafyllos Chavakis
Journal:  J Innate Immun       Date:  2021-08-24       Impact factor: 7.349

5.  You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.

Authors:  Joseph V Varre; William L Holland; Scott A Summers
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2022-02-23       Impact factor: 5.228

Review 6.  Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity.

Authors:  W Timothy Garvey; Jeffrey I Mechanick
Journal:  Obesity (Silver Spring)       Date:  2020-03       Impact factor: 5.002

7.  AdR1-TG/TALLYHO mice have improved lipid accumulation and insulin sensitivity.

Authors:  Nanlan Luo; Xiangdong Wang; Wei Zhang; W T Garvey; Yuchang Fu
Journal:  Biochem Biophys Res Commun       Date:  2013-03-21       Impact factor: 3.575

8.  Divergent roles for adiponectin receptor 1 (AdipoR1) and AdipoR2 in mediating revascularization and metabolic dysfunction in vivo.

Authors:  Jennifer L Parker-Duffen; Kazuto Nakamura; Marcy Silver; Maria A Zuriaga; Susan MacLauchlan; Tamar R Aprahamian; Kenneth Walsh
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

9.  Correlation of serum adiponectin and adiponectin gene polymorphism with metabolic syndrome in Chinese adolescents.

Authors:  P Li; R Jiang; L Li; C Liu; F Yang; Y Qiu
Journal:  Eur J Clin Nutr       Date:  2014-07-30       Impact factor: 4.016

Review 10.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.